Champions Oncology (CSBR) AI Stock Analysis

• Market Cap: $94.30M
• Dividend Yield: N/A
• Average Volume (3M): 17.98K
• Price to Earnings (P/E): 40.8
• Beta (1Y): 0.42
• Revenue Growth: 9.06%
• EPS Growth: N/A
• Country: US
• Employees: 210
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 13,886,326
• 10 Day Avg. Volume: 35,034
• 30 Day Avg. Volume: 17,980
• PEG Ratio: -0.13
• Price to Book (P/B): 25.89
• Price to Sales (P/S): 1.72
• P/FCF Ratio: 13.96
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 1.56
• Enterprise Value/Gross Profit: 3.28
• Enterprise Value/Ebitda: 23.57
• 1Y Price Target: $12.00
• Price Target Upside: 80.72% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $7.50 ▲(12.95% Upside)

The overall stock score of 61 reflects a balanced view of Champions Oncology's current position. The most significant factor is the company's financial performance, which shows profitability improvements but is weighed down by high leverage and cash flow challenges. Technical analysis supports a slightly bullish outlook, while the earnings call provides optimism with strong revenue growth and strategic investments. However, the high P/E ratio suggests overvaluation, limiting upside potential.

Positive Factors

Revenue Growth

The 11% YoY revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Improved Gross Margin

Higher gross margins reflect improved operational efficiencies, enhancing profitability and competitive positioning over time.

Strategic Investments

Investments in data platforms can drive innovation and strengthen partnerships, positioning the company for future growth.

Negative Factors

High Leverage

Significant leverage increases financial risk, potentially impacting the company's ability to invest in growth opportunities.

Cash Flow Challenges

Negative cash flow from operations can strain liquidity, limiting the company's ability to finance new projects without external funding.

Declining Revenue Growth

Negative revenue growth suggests challenges in maintaining market share, which could hinder long-term financial performance.

Champions Oncology Business Overview & Revenue Model

Company Description

Champions Oncology (CSBR) is a biotechnology company that specializes in personalized medicine, particularly in the field of oncology. The company develops advanced technology platforms, including its proprietary TumorGraft® technology, which allows for the creation of patient-derived tumor models for use in drug development and treatment selection. By providing solutions that enhance the understanding of cancer biology and treatment responses, Champions Oncology serves pharmaceutical companies, academic institutions, and healthcare providers globally.

How the Company Makes Money

Champions Oncology generates revenue primarily through its services related to tumor models and personalized medicine solutions. The company earns money from its TumorGraft platform by offering preclinical services to pharmaceutical companies, which include drug efficacy testing and biomarker studies. Additionally, the company has established partnerships with various pharmaceutical firms that may involve collaborative research agreements and licensing deals, contributing to its revenue streams. The company also provides consulting services and engages in strategic collaborations that can enhance its earnings potential. Overall, its revenue model is centered on providing high-value, data-driven insights that help accelerate the drug development process for oncology therapies.

Champions Oncology Financial Statement Overview

Summary

Champions Oncology has shown improvements in profitability and return on equity, but faces challenges with declining revenue growth and high leverage. The company's ability to generate cash flow is under pressure, as evidenced by the significant decline in free cash flow growth. While there are positive signs of recovery, particularly in profitability, the high debt levels and cash flow issues could pose risks if not addressed.

Income Statement

Champions Oncology has shown a mixed performance in its income statement. The company has managed to improve its gross profit margin to 50.15% in 2025, indicating efficient cost management. However, the revenue growth rate has been negative at -2.81%, reflecting a decline in sales. The net profit margin improved to 8.26% in 2025, a significant turnaround from previous losses, suggesting enhanced profitability. Despite these improvements, the EBIT and EBITDA margins remain relatively low, indicating potential challenges in operational efficiency.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.62 in 2025, indicating significant leverage and potential financial risk. However, the return on equity is strong at 124.63%, driven by improved net income. The equity ratio stands at 11.66%, suggesting a moderate level of equity financing. Overall, while the company has improved its profitability, the high leverage poses a risk to financial stability.

Cash Flow

The cash flow statement shows a concerning trend with a significant decline in free cash flow growth at -628.87% in 2025. The operating cash flow to net income ratio is 0.31, indicating that operating cash flow covers net income, but not robustly. The free cash flow to net income ratio is healthy at 94.73%, suggesting that the company is generating sufficient free cash flow relative to its net income. Despite this, the negative growth in free cash flow is a potential red flag.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	56.94M	50.16M	53.87M	49.11M	41.04M
Gross Profit	26.91M	20.75M	24.34M	25.48M	19.59M
EBITDA	6.29M	-5.41M	-2.07M	3.00M	2.02M
Net Income	4.70M	-7.28M	-5.33M	548.00K	362.00K
Balance Sheet
Total Assets	32.34M	26.13M	34.31M	35.38M	27.59M
Cash, Cash Equivalents and Short-Term Investments	9.79M	2.62M	10.12M	9.01M	4.69M
Total Debt	6.11M	7.43M	8.60M	9.47M	9.60M
Total Liabilities	28.57M	28.04M	29.68M	26.28M	20.16M
Stockholders Equity	3.77M	-1.90M	4.64M	9.10M	7.43M
Cash Flow
Free Cash Flow	7.00M	-6.97M	1.08M	4.11M	-4.96M
Operating Cash Flow	7.39M	-6.14M	3.96M	6.50M	-1.68M
Investing Cash Flow	-389.00K	-836.00K	-2.87M	-2.38M	-3.17M
Financing Cash Flow	170.00K	-527.00K	11.00K	207.00K	1.20M

Champions Oncology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.64
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSBR, the sentiment is Positive. The current price of 6.64 is below the 20-day moving average (MA) of 6.84, below the 50-day MA of 6.70, and below the 200-day MA of 6.97, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 50.88 is Neutral, neither overbought nor oversold. The STOCH value of 28.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CSBR.

Champions Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSBR	61 Neutral	$94.30M	40.81	102.74%	―	9.06%	―
PLX	59 Neutral	$160.84M	28.78	12.64%	―	35.42%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANIX	49 Neutral	$112.58M	-9.92	-57.94%	―	―	11.78%
ATOS	45 Neutral	$84.35M	-2.78	-48.89%	―	―	-9.42%
SAVA	42 Neutral	$103.38M	-0.97	-85.44%	―	―	-505.96%

Champions Oncology Corporate Events

Champions Oncology Holds Annual Stockholders Meeting

On October 16, 2025, Champions Oncology, Inc. held its Annual Meeting of Stockholders, where key decisions were made. The company’s seven director nominees were elected for a one-year term, and the appointment of EisnerAmper LLP as the independent registered public accounting firm was ratified. Additionally, a non-binding advisory resolution on executive compensation was approved, indicating shareholder support for the company’s leadership and strategic direction.

The most recent analyst rating on (CSBR) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Champions Oncology stock, see the CSBR Stock Forecast page.